Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Neoplasms by Histologic Type

Hematologic Diseases

Myeloproliferative Disorders

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Myeloid Leukemia

Chronic Graft Versus Host Disease

Chronic Myeloid Leukemia

Chronic Myeloproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Dasatinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

We will give 50mg of dasatinib orally daily for 6 months

Dasatinib 50 MG

David Gomez, MD

David Gomez-Almaguer, MD

Paola Santana, MD

Manuel Solano, MD

Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.

We will give 50mg of dasatinib daily since the diagnosis for up to 6 months, for the first 2-4 weeks we will evaluate hematic biometry to registry hematic response, at months 3 and 6 a BCR/ABL PCR will be taken to evaluate molecular response.

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Molecular Response define as BCR/ABL \<1%

Hospital Universitario Dr. Jose E. Gonzalez

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia	NCT03216070	Chronic Myeloge...	Dasatinib 50 MG	16 Years -	Hospital Universitario Dr. Jose E. Gonzalez
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia	NCT03216070	Chronic Myeloge...	Dasatinib 50 MG	16 Years -	Hospital Universitario Dr. Jose E. Gonzalez

Spots Global Cancer Trial Database for dasatinib 50 mg